Pharmaceuticals

Surge In Cancer Cases Fuels Expansion Of Generic Oncology Drugs Is Contributing To Changes In The Rituximab Biosimilars Market

May 4, 2026May 4, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Anticipated Rise In Market Value Of The Rituximab Biosimilars Market During The Forecast Period?

The rituximab biosimilars market size has experienced swift expansion in recent years. It is anticipated to increase from $3.42 billion in 2025 to reach $3.84 billion by 2026, exhibiting a compound annual growth rate (CAGR) of 12.5%. The expansion witnessed in previous periods can be attributed to the substantial expense of originator rituximab, the escalating prevalence of non-hodgkin’s lymphoma, the rising incidence of chronic lymphocytic leukemia, heightened understanding of autoimmune disease management, and restricted availability of sophisticated biologics.

The rituximab biosimilars market is expected to experience substantial growth over the next few years. It is projected to expand to $6.26 billion by 2030, achieving a compound annual growth rate (CAGR) of 13.0%. This anticipated growth during the forecast period is largely driven by factors such as the introduction of new biosimilar formulations, the expansion of subcutaneous delivery methods, increasing adoption in emerging markets, growing government and insurance support for biosimilars, and their integration into hospital and specialty pharmacy programs. Prominent trends throughout this period include the rising acceptance of rituximab biosimilars for the treatment of oncology and autoimmune diseases, the wider availability of subcutaneous administration and pre-filled delivery systems, an increasing preference for more affordable monoclonal antibody alternatives, the expanded application of antibody-drug conjugates (ADCs) in targeted therapy, and improved distribution channels through hospitals and retail pharmacies.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3430&type=smp

What Factors Are Contributing To The Growth Of The Rituximab Biosimilars Market?

The increasing occurrence of non-Hodgkin’s lymphoma (NHL) is projected to boost the expansion of the rituximab biosimilars market moving ahead. Non-Hodgkin’s lymphoma is defined as a form of cancer originating in lymphocytes, which are white blood cells crucial to the body’s immune system. The increase in NHL cases stems from higher incidence rates, especially among older demographics, along with various lifestyle and environmental contributors. Rituximab Biosimilars work by specifically targeting and eliminating CD20-positive B cells, leading to a reduction in tumor size, better regulation of the immune system, and offering a more affordable and accessible treatment alternative for patients with non-Hodgkin’s lymphoma (NHL), ultimately improving treatment results and quality of life. For example, in January 2024, the American Cancer Society, a US-based cancer advocacy organization, reported that around 80,620 individuals (44,590 men and 36,030 women) were anticipated to be diagnosed with non-Hodgkin lymphoma, with an estimated 20,140 deaths (11,780 men and 8,360 women), and the lifetime risk of developing this cancer stands at approximately 1 in 42 for men and 1 in 52 for women. Consequently, the rising prevalence of non-Hodgkin’s lymphoma is propelling the growth of the rituximab biosimilars market.

What Segment Categories Shape The Rituximab Biosimilars Market Segment Landscape?

The rituximab biosimilars market covered in this report is segmented –

1) By Route Of Administration: Subcutaneous, Intravenous

2) By Application: Non-Hodgkin’s Lymphoma, Chronic Lymphocytic Leukemia, Rheumatoid Arthritis, Other Applications

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Mail Order

Subsegments:

1) By Subcutaneous: Pre-filled Syringes, Injection Pens

2) By Intravenous: IV Infusion Solutions, IV Push Formulations

What Trends Are Affecting The Direction Of The Rituximab Biosimilars Market?

Leading companies in the rituximab biosimilars market are prioritizing the development of innovative products through strategic collaborations to improve accessibility and offer more economical treatment solutions for individuals with various immunological and oncological conditions. Partnering with established entities assists companies in expediting commercialization, leveraging collective knowledge in regulatory approvals and distribution, and efficiently introducing biosimilars to the market, thereby increasing patient access and market penetration. For instance, in July 2023, Dr. Reddy’s Laboratories joined forces with its partner Fresenius Kabi to commercialize its proposed rituximab biosimilar in the US. This collaboration aims to launch a biosimilar variant of rituximab, providing a more affordable and accessible treatment option for patients. The introduction of a rituximab biosimilar in the United States could potentially enhance access to this vital treatment for patients suffering from conditions such as rheumatoid arthritis, non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, pemphigus vulgaris, granulomatosis with polyangiitis, and microscopic polyangiitis.

Who Are The Companies Operating Across The Rituximab Biosimilars Market Value Chain?

Major companies operating in the rituximab biosimilars market are Novartis AG, Pfizer, BIOCAD, Shanghai Henlius Biotech Inc., Innovent Biologics Inc., Cadila Pharmaceuticals, Hetero Drugs Limited, Dr. Reddy’s Laboratories, Shanghai Fosun Pharmaceutical (Group) Co. Ltd., Reliance Life Sciences India, Zenotech Laboratories, Celltrion, Biocad, MABION S.A., Amgen, Teva Pharmaceuticals, Celltrion Healthcare, Coherus BioSciences, Aryogen Biopharma, TR-Pharm, Hikma Pharmaceuticals plc.

Get The Full Rituximab Biosimilars Market Report:

https://www.thebusinessresearchcompany.com/report/rituximab-biosimilar-global-market-report

Which Region Is The Leading Market For The Rituximab Biosimilars Market?

North America was the largest region in the rituximab biosimilars market in 2025. Middle East is expected to be the fastest-growing region in the rituximab biosimilars market report during the forecast period. The regions covered in the rituximab biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Rituximab Biosimilars Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/rituximab-biosimilar-global-market-report

Browse Through More Reports Similar to the Global Rituximab Biosimilars Market 2026, By The Business Research Company

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Oncology Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report

Oral Biologics And Biosimilars Market 2026

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795